Article Figures & Data
Figures
- FIGURE 1.
Example of multimetastatic patient with tibial metastasis of PC. A 75-y-old man who received androgen deprivation therapy was scanned with 68Ga-PSMA PET/CT for restaging because of elevated serum PSA level (GS, 4 + 3 = 7; PSA, 25.17 ng/mL). Pathologic 68Ga-PSMA uptake in sclerotic metastases was seen to have localized in right fifth rib (arrows on axial CT [F] and axial fusion [G]), T1 vertebra (arrow on fusion [B]), T9–T11 vertebrae (arrows on sagittal CT [C] and sagittal fusion [D]), and right iliac crest (arrows on axial CT [J] and axial fusion [K]) on limited whole-body 68Ga-PSMA PET/CT images (maximum-intensity projection [A]). Additionally, sclerotic metastasis in right distal tibia with intense 68Ga-PSMA uptake (arrows on sagittal CT [H], sagittal fusion [I], and coronal PET [E]) was seen on lower-limb 68Ga-PSMA PET/CT images. Stage of disease did not change with tibial metastasis. However, patient had leg pain for almost 4 wk and received external radiotherapy for palliation.
- FIGURE 2.
Receiver-operating-characteristic curves for PSA.
Tables
Characteristic Data Age (y) Median 62 Range 50–92 GS (n) 3 + 3 = 6 70 (9.9%) 3 + 4 = 7 122 (17.4%) 4 + 3 = 7 116 (16.5%) 3 + 5 = 8 12 (2%) 4 + 4 = 8 117 (16.7%) 5 + 3 = 8 4 (0.5%) 4 + 5 = 9 128 (18.3%) 5 + 4 = 9 36 (5.1%) 5 + 5 = 10 14 (1.9%) Unknown 82 (11.7%) PSA at time of scan (ng/mL) Median 9.3 Range 0.003–4,337 PET/CT indication (n) Staging 249 Restaging 376 Therapy response 76 Symptom-positive patients (n) 55 Symptom-negative patients (n) 546 Result Data 68Ga-PSMA PET/CT-positive patients (n) 601 (85.7%) Median PSA level (ng/mL) 12 (range, 0.003–4,337) Median GS 7 (range, 5–10) 68Ga-PSMA PET/CT-negative patients (n) 100 (14.3%) Median PSA level (ng/mL) 0.8 (range, 0.003–18.5) Median GS 8 (range, 5–10) Metastatic sites of patients (n) Prostate/prostate bed 400 (57%) Seminal vesicle 58 (8.2%) Bladder/rectum 29 (4.1%) Bone 278 (39.6%) Oligometastatic (<4 lesions) 108 (15.4%) Multimetastatic (≥4 lesions) 170 (24.2%) Lymph nodes 300 (42.7%) Supradiaphragmatic 91 (12.9%) Abdominal 128 (18.2%) Pelvic 272 (38.8%) Lung 36 (5.1%) Liver 24 (3.4%) Other 15 (2.1%) Patient with bone metastasis (n) 278 (39.6%) Oligometastatic 108 (15.4%) Median PSA level (ng/mL) 5.9 (range, 0.003–971.9) Median GS 7 (range, 6–10) Multimetastatic 170 (24.2%) Median PSA level (ng/mL) 25.8 (range, 0.003–4,337) Median GS 8 (range, 5–10) Multimetastatic (without lower-limb metastasis) 109 (15.5%) Median PSA level (ng/mL) 38.1 (range, 0.008–3,227) Median GS 8 (range, 6–10) Multimetastatic (with lower- limb metastasis) 61 (8.7%) Median PSA level (ng/mL) 78 (range, 1.16–4,337) Median GS 9 (range, 5–10) Distribution of lower-limb metastasis (n) Distal femur 54 Tibia 20 Fibula 24 Calcaneus 1 Lower-limb metastasis (ratio) Symptom-positive patients 70.9% (39/55) Symptom-negative patients 4% (22/546) PSA ≤ 24 ng/mL 23.4% PSA > 24 ng/mL 76.6%
